Edge Biosystems Inc.

San Jose, CA

UEI
R6MTUWQQF8L4
CAGE
1PCJ9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

FY2025 rankings
Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2032 Concourse Dr, San Jose, CA 95131, USA
Website
edgebio.com
Founded
1989
Employees
11-50
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $77,585
FY2025 $153,820
FY2024 $93,009
FY2023 $154,066

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Defense Health Agency $77,585

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
A chaperonin/osmolyte protein folding screen - sttr phase I R41GM080074 National Institutes of Health $100,000

Similar vendors

About the company

Edge Biosystems Inc., a San Jose-based for-profit manufacturer of laboratory supplies and DNA sequencing products, operates as a prime contractor supplying specialized diagnostic reagents and laboratory equipment to the Defense Health Agency and Department of Army Medical Command on a full-and-open, non-set-aside basis. The company holds no subcontracting footprint and competes exclusively as a prime across its federal portfolio.

Edge Biosystems manufactures in-vitro diagnostic substances and DNA analysis consumables, primarily Performa DTR Ultra 96-well plates and related dye terminator removal (DTR) equipment for forensic DNA sequencing and medical examination operations. Concrete representative work includes a $2.9 million single-award BPA established September 1, 2025, through August 31, 2030, with the Defense Health Agency to supply DTR Ultra 96-well plates and laboratory equipment to the Office of the Armed Forces Medical Examiner System; a prior $4.5 million single-award BPA (August 2020 through August 2025) that generated approximately $350,000 in call orders for similar products; and a $24.2 million equipment maintenance agreement with the National Cancer Institute awarded in August 2021. Recent activity includes a $23,438.75 BPA call from the Defense Health Agency on March 6, 2026, for DNA sequencing consumables supporting forensic and diagnostic operations.

Customer concentration heavily favors the Defense Health Agency and Army-affiliated customers. The top two customer agencies account for 72% of awards by count and 99% of combined potential value: the Defense Health Agency (27 awards, $10.2 million combined potential value) and the Department of the Army Medical Command (21 awards, $4.5 million). The remaining portfolio spans the National Institutes of Health, with scattered work under National Cancer Institute, NIAID, and NIDA vehicles totaling less than $300 thousand across twelve awards.

Edge Biosystems executes work primarily through two legacy indefinite-delivery contract vehicles with the Army Medical Command — IDC W81XWH17D0035 (11 task orders, $961 thousand) and IDC W81XWH11D0044 (6 task orders, $611 thousand) — and the prior DHA BPA W81XWH20A9065 (12 task orders, $595 thousand), alongside smaller NIH research vehicles. The company's product mix clusters in NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing, 38 awards) and PSC 6640 (Laboratory Equipment and Supplies, 26 awards), with secondary exposure in biological product manufacturing and testing laboratory services.

Activity has remained modest and relatively flat, ranging from two to five awards per year over the past five years, with 85 total prime awards carrying $15.1 million in combined potential value and $4 million in obligated dollars (26% draw). The recompete window shows minimal churn: only one award with ultimate completion in the next twenty-four months, valued at $23 thousand, indicating stable contract tenure but limited growth pipeline outside the newly awarded 2030-expiring DHA BPA.

Quick answers

Is Edge Biosystems Inc. registered in SAM.gov?

Yes. Edge Biosystems Inc.'s SAM.gov registration is active through February 2, 2027.

What is Edge Biosystems Inc.'s CAGE code?

Edge Biosystems Inc.'s CAGE code is 1PCJ9, and its Unique Entity ID (UEI) is R6MTUWQQF8L4.

How much has Edge Biosystems Inc. received in federal contracts?

Federal contracts obligated $153,820 to Edge Biosystems Inc. in fiscal year 2025 and $478,479 in fiscal years 2023 through 2027.

How does Edge Biosystems Inc. rank among federal contractors?

Edge Biosystems Inc. ranked #80 in NAICS 325413 in FY2025.

What is Edge Biosystems Inc.'s most recent federal award?

Edge Biosystems Inc.'s most recent federal contract award is Performa DTR ultra 96-well plate kit (HT942726FE068), from Defense Health Agency, on May 13, 2026.

On GovTribe

See Edge Biosystems Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe